Background. Despite intense efforts to understand the immunopathology of sepsis, no clinically reliable diagnostic biomarkers exist. Multiple whole-blood gene expression studies have sought sepsis-associated molecular signatures, but these have not yet resolved immune phenomena at the cellular level. Using single-cell RNA sequencing (scRNA-Seq) to profile peripheral blood mononuclear cells (PBMCs), we identified a novel cellular state enriched in patients with sepsis.
Methods. We performed scRNA-Seq on PBMCs from 26 patients with sepsis and 47 controls at two hospitals (mean age 57.5 years, SD 16.6; 54% male; 82% white), analyzing >200,000 single cells in total on a 10× Genomics platform. We identified immune cell states by stepwise clustering, first to identify the major immune cell types, then clustering each cell type into substates. Substate abundances were compared between cases and controls using the Wilcoxon rank-sum test.
Results. We identified 18 immune cell substates (Figure 1a ), including a novel CD14+ monocyte substate (MS1) that is enriched in patients with sepsis ( Figure 1b ). The fractional abundance of the MS1 substate alone (ROC AUC 0.88) outperformed published bulk transcriptional signatures in identifying sepsis (AUC 0.68-0.82) across our clinical cohorts. Deconvolution of publicly available bulk transcriptional data to infer the abundance of the MS1 substate externally validated its accuracy in predicting sepsis of various etiologies across diverse geographic locations (Figure 1c ), matching the best previously identified bulk signatures. Flow cytometry using cell surface markers unique to MS1 confirmed its marked expansion in sepsis, facilitating quantitation and isolation of this substate for further study.
Conclusion. This study demonstrates the utility of scRNA-Seq in discovering disease-associated cytologic signatures in blood and identifies a cell state signature for sepsis in patients with bacterial infections. This novel monocyte substate matched the performance of the best bulk transcriptional signatures in classifying patients as septic, and pointed to a specific cell state for further molecular and functional characterization of sepsis immunopathogenesis.
Disclosures. All Authors:
No reported Disclosures. Background. Multi-drug-resistant (MDR) P. aeruginosa (PA) infections continue to cause significant morbidity and mortality in various patient groups including those with malignancies. Predicting antimicrobial resistance (AMR) from whole-genome sequencing data if done rapidly, could aid in providing optimal care to patients.
Machine Learning Approaches to Predicting Resistance in Pseudomonas aeruginosa
Methods. To better understand the connections between DNA variation and phenotypic AMR in PA, we developed a new algorithm, variant mapping and prediction of antibiotic resistance (VAMPr), to build association and machine learning prediction models of AMR based on publicly available whole-genome sequencing and antibiotic susceptibility testing (AST) data. A validation cohort of contemporary PA bloodstream isolates was sequenced and AST was performed. Accuracy of predicting AMR for various PA-drug combinations was calculated.
Results. VAMPr was built from 3,393 bacterial isolates (83 PA isolates included) from 9 species that contained AST data for 29 antibiotics. 14,615 variant genotypes were identified within the dataset and 93 association and prediction models were built. 120 PA bloodstream isolates from cancer patients were included for analysis in the validation cohort. ~15% of isolates were carbapenem resistant and ~20% were quinolone resistant. For drug-isolate combinations where >100 isolates were available, machine-learning prediction accuracies ranged from 75.6% (PA and ceftazidime; 90/119 correctly predicted) to 98.1% (PA and amikacin; 105/107 correctly predicted). Machine learning accurately identified known variants that strongly predicted resistance to various antibiotic classes. Examples included specific gyrA mutations (T83I; P < 0.00001) and quinolone resistance.
Conclusion. Machine learning predicted AMR in P. aeruginosa across a number of antibiotics with high accuracy. Given the genomic heterogeneity of PA, increased genomic data for this pathogen will aid in further improving prediction accuracy across all antibiotic classes.
Disclosures. Samuel L. Aitken, PharmD, Melinta Therapeutoics: Grant/Research Support, Research Grant; Merck, Sharpe, and Dohme: Advisory Board; Shionogi: Advisory Board rising detection of histidine-rich protein 2 (HRP2) gene deletions in Plasmodium spp. HRP2 is the most commonly used antigen in RDTs and deletion of this gene would render many RDTs obsolete.
Methods. SHERLOCK leverages the endonucleases of CRISPR-associated microbial adaptive immunity. Cas12a is an RNA-guided, DNA-cleaving enzyme, which can be programmed with guide RNAs to cleave nontarget reporter ssDNA. We exploit the nonspecific degradation of labeled ssDNA to detect the presence of the dsDNA target that activated Cas12a (Figure 1 ). Recombinase polymerase amplification (RPA) coupled with Cas12a detection enables a lower LOD. Plasmodium falciparum whole genomic DNA was compared with parasites cultured in red blood cells (RBCs) with known parasitemia and boiled at 95°C for 5 minutes for lysis of RBCs/parasites then diluted 1:2.5 to prevent solidification.
Results. This SHERLOCK assay detected simulated Plasmodium falciparum infection at attomolar LODs when applied to whole genomic DNA and simulated samples of infected RBCs spiked into whole blood. The genomic assay detected down to 0.2 parasites/microliter and the simulated sample detected to 10 parasites/microliter in the final reaction volume. In comparison, LODs from the initial input volume was 5aM and 250aM, respectively (Figure 2) .
Conclusion. We demonstrate an isothermal nucleic acid detection platform capable of diagnosis in 60 minutes in a one-pot assay requiring minimal sample preparation and reaching an LOD recommended by the WHO for malaria eradication. In summary, we illustrate the utility of the SHERLOCK platform in application to malaria and global health.
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Measuring Influenza HA Stem-Specific ADCC in Human Sera Using Novel Stabilized Stem Nanoparticle Probes
Maria K. Smatti, MSc; Gheyath Nasrallah, PhD; Asmaa Althani, PhD and Hadi Yassine, PhD; Qatar University, Doha, Ad Dawhah, Qatar Session: 183. Innovative Diagnostics Friday, October 4, 2019: 2:30 PM Background. Generating a vaccine that confers complete protection and overcomes the high variability among influenza viruses is the major goal in designing a universal influenza vaccine. Currently, there is considerable interest in the broadly neutralizing antibodies (bNAb) targeting the conserved HA stem region. These antibodies have been shown to activate cellular immune responses, such as antibody-dependent cellular cytotoxisity (ADCC), in addition to their neutralization activity. We had previously demonstrated that immunization with H1-based stabilized stem (SS) nanoparticles (np) protects against heterosubtypic lethal challenge with H5N1 influenza virus, despite the absence of detectable H5N1 neutralizing activity. Here, we utilized these novel SS np probes to develop a new protocol to assess the ADCC activity mediated by stem-directed antibodies in human sera.
Methods. Human sera samples were initially screened for binding reactivity to H1 SS trimer using ELISA procedure. Of these, selected samples representing high, moderate, and low binders were further characterized for binding to H1 and H5 SS their corresponding Δstem (Ile45Arg/Thr49Arg) probes, and were analyzed for ADCC activity using a reporter bioassay.
Results. The initial screening revealed 82% (73/90) seroprevalence of anti-HA (H1) stem epitope antibodies, as determined by the differential binding to HA SS and it corresponding epitope-mutant probe. Using equimolar amounts, the multivalent presentation of HA SS on np probes induced significantly higher ADCC activity compared with the monovalent SS probes (2-to 6-fold increase). Further, ADCC activity was similarly reported against different influenza group 1 subtypes: H1, H2, and H5. Importantly, ADCC was mediated mainly by antibodies targeting the bNAb-epitope on the HA stem. In conclusion, we developed an assay to measure stem-specific ADCC activity using SS np probes.
Conclusion. Our results indicate a high prevalence of HA-stem antibodies with cross-reactive ADCC activity. Such assay could be utilized in the assessment of next-generation influenza vaccines.
Disclosures. All Authors:
